SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • March 13th, 2024 • Liquidia Corp • Pharmaceutical preparations
Contract Type FiledMarch 13th, 2024 Company IndustryThis SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this “Amendment”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • August 10th, 2023 • Liquidia Corp • Pharmaceutical preparations
Contract Type FiledAugust 10th, 2023 Company IndustryThis SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this “Amendment”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.